TransMedics Group (TMDX) Stock Price, News & Analysis

Company Overview

TransMedics Group, Inc. is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms. The OCS Heart system is approved by the U.S. Food and Drug Administration (FDA) and has received CE Mark clearance in Europe for heart transplantation. By maintaining the donor heart in a perfused, beating state outside the body, the system allows clinicians to assess organ function prior to implantation. The OCS Lung platform similarly supports donor lungs with normothermic perfusion and has FDA approval and CE Mark clearance for clinical use.

In addition to its heart and lung preservation products, TransMedics is developing an investigational OCS Liver system designed to extend preservation times and improve viability assessments for donor livers. The company is conducting clinical trials globally to evaluate safety and efficacy, with the goal of securing regulatory approvals in key markets. TransMedics maintains commercial operations in North America and Europe and is working to expand its footprint in Asia-Pacific and other regions.

Leadership at TransMedics includes Waleed Hassanein, M.D., who serves as President and Chief Executive Officer. Dr. Hassanein brings extensive experience in the medical device industry, having led global commercial and clinical strategy teams prior to joining the company. Under his direction, TransMedics continues to invest in research and development, partnering with transplant centers and research institutions to advance organ care technologies and address the growing need for viable donor organs worldwide.

Key Stats

• Today's Range: $71.61 to $77.90
• 50-Day Range: $72.90 to $148.00
• 52-Week Range: $70.00 to $156.00
• Volume: 2.65 million shs
• Average Volume: 1.29 million shs
• Market Capitalization: $2.52 billion
• P/E Ratio: 29.76
• Dividend Yield: N/A
• Price Target: $135.00
• Consensus Rating: Moderate Buy

TransMedics Group Stock Analysis - MarketRank™

TransMedics Group scored higher than 89% of companies evaluated by MarketBeat, and ranked 44th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

TransMedics Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 6 buy ratings, 6 hold ratings, and no sell ratings.

Upside Potential

TransMedics Group has a consensus price target of $135.00, representing about 85.2% upside from its current price of $72.90.

Amount of Analyst Coverage

TransMedics Group has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 54.44%

Earnings Growth

Earnings for TransMedics Group are expected to grow by 54.44% in the coming year, from $2.48 to $3.83 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of TransMedics Group is 16.57, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.44.

Price to Earnings Ratio vs. Sector

The P/E ratio of TransMedics Group is 16.57, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.56.

Price to Book Value per Share Ratio

TransMedics Group has a P/B Ratio of 5.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for TMDX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TransMedics Group does not currently pay a dividend.

Dividend Growth

TransMedics Group does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: -0.36

News Sentiment

TransMedics Group has a news sentiment score of -0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 28 news articles for TransMedics Group this week, compared to 5 articles on an average week.

Search Interest

18 people have searched for TMDX on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.

MarketBeat Follows

14 people have added TransMedics Group to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, TransMedics Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,353,002.00 in company stock.

Percentage Held by Insiders

6.90% of the stock of TransMedics Group is held by insiders.

Percentage Held by Institutions

99.67% of the stock of TransMedics Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TMDX Stock Analysis - Frequently Asked Questions

How have TMDX shares performed this year?

TransMedics Group's stock was trading at $121.65 at the start of the year. Since then, TMDX shares have decreased by 40.1% and is now trading at $72.90.

How were TransMedics Group's earnings last quarter?

TransMedics Group, Inc. (NASDAQ:TMDX) posted its quarterly earnings data on Tuesday, May, 5th. The company reported $0.30 earnings per share for the quarter, missing the consensus estimate of $0.62 by $0.32. The company's revenue was up 21.2% compared to the same quarter last year.
Read the conference call transcript.

When did TransMedics Group IPO?

TransMedics Group (TMDX) raised $91 million in an initial public offering on Thursday, May 2nd 2019. The company issued 5,690,000 shares at $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

Who are TransMedics Group's major shareholders?

Top institutional investors of TransMedics Group include Dimensional Fund Advisors LP (1.50%), Wasatch Advisors LP (1.00%), Emerald Advisers LLC (0.99%) and Principal Financial Group Inc. (0.67%). Insiders that own company stock include James R Tobin, Waleed H Hassanein, Nicholas Corcoran, Miriam Provost, Stephen Gordon, Tamer I Khayal, Gerardo Hernandez, Anil P Ranganath, David Weill, Stephanie Lovell and Edward M Basile.
View institutional ownership trends.

How do I buy shares of TransMedics Group?

Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of TransMedics Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that TransMedics Group investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Invesco QQQ (QQQ), Broadcom (AVGO), Arista Networks (ANET) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 5/05/2026
• Today: 5/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:TMDX
• CIK: 1756262
• Web: www.transmedics.com
• Phone: (978) 552-0900
• Fax: N/A
• Employees: 210
• Year Founded: 1998

Price Target and Rating

• Average Price Target for TransMedics Group: $135.00
• High Price Target: $175.00
• Low Price Target: $85.00
• Potential Upside/Downside: +85.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): $4.90
• Trailing P/E Ratio: 16.57
• Forward P/E Ratio: 29.40
• P/E Growth: N/A
• Net Income: $190.29 million
• Net Margins: 27.04%
• Pretax Margin: 17.76%
• Return on Equity: 24.01%
• Return on Assets: 9.48%

Debt

• Debt-to-Equity Ratio: 1.06
• Current Ratio: 7.14
• Quick Ratio: 6.59

Sales & Book Value

• Annual Sales: $605.49 million
• Price / Sales: 4.16
• Cash Flow: $3.02 per share
• Price / Cash Flow: 24.17
• Book Value: $13.79 per share
• Price / Book: 5.29

Miscellaneous

• Outstanding Shares: 34,530,000
• Free Float: 32,149,000
• Market Cap: $2.52 billion
• Optionable: Optionable
• Beta: 2.07